Drugs Made In America Acquisition II Corp. (NASDAQ: DMIIR) Stock Competitors & Peer Comparison
See DMIIR's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Financial - Conglomerates Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for DMIIR and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| DMIIR | $0.05 | -8.73% | 3.2M | 0.25 | $0.20 | N/A |
| FRHC | $178.85 | +0.95% | 11.4B | 71.25 | $2.51 | N/A |
| RILYK | $25.23 | +0.16% | 787.6M | N/A | N/A | N/A |
| RILYM | $25.11 | +0.00% | 753M | N/A | N/A | N/A |
| DMIIU | $10.26 | +0.29% | 651.3M | 50.25 | $0.20 | N/A |
| DMII | $10.21 | -0.10% | 650.4M | 72.93 | $0.14 | N/A |
| RILYO | $25.13 | -0.02% | 573.5M | N/A | N/A | N/A |
| VACHU | $14.50 | +0.00% | 475.5M | N/A | N/A | N/A |
| LEGT-UN | $18.00 | +0.90% | 467.4M | N/A | N/A | N/A |
| XRPNW | $1.83 | +15.09% | 400.1M | 18.75 | $0.10 | N/A |
Stock Comparison
Freedom Holding Corp. (NASDAQ: FRHC)
DMIIR vs FRHC Comparison November 2026
Drugs Made In America Acquisition II Corp. (NASDAQ: DMIIR) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMIIR stands at 3.2M. In comparison, FRHC has a market cap of 11.4B. Regarding current trading prices, DMIIR is priced at $0.05 on the NASDAQ, while FRHC trades at $178.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMIIR currently has a P/E ratio of 0.25, whereas FRHC's P/E ratio is 71.25. In terms of profitability, DMIIR's ROE is +0.03%, compared to FRHC's ROE of +0.11%. Regarding short-term risk, DMIIR is less volatile compared to FRHC. This indicates lower risk in terms of short-term price fluctuations for DMIIR.Check FRHC's competition here
B. Riley Financial, Inc. 5.50% Senior Notes Due 2026 (NASDAQ: RILYK)
DMIIR vs RILYK Comparison November 2026
Drugs Made In America Acquisition II Corp. (NASDAQ: DMIIR) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMIIR stands at 3.2M. In comparison, RILYK has a market cap of 787.6M. Regarding current trading prices, DMIIR is priced at $0.05 on the NASDAQ, while RILYK trades at $25.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMIIR currently has a P/E ratio of 0.25, whereas RILYK's P/E ratio is N/A. In terms of profitability, DMIIR's ROE is +0.03%, compared to RILYK's ROE of +94.15%. Regarding short-term risk, DMIIR is more volatile compared to RILYK. This indicates higher risk in terms of short-term price fluctuations for DMIIR.Check RILYK's competition here
B. Riley Financial, Inc. - 6.37 (NASDAQ: RILYM)
DMIIR vs RILYM Comparison November 2026
Drugs Made In America Acquisition II Corp. (NASDAQ: DMIIR) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMIIR stands at 3.2M. In comparison, RILYM has a market cap of 753M. Regarding current trading prices, DMIIR is priced at $0.05 on the NASDAQ, while RILYM trades at $25.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMIIR currently has a P/E ratio of 0.25, whereas RILYM's P/E ratio is N/A. In terms of profitability, DMIIR's ROE is +0.03%, compared to RILYM's ROE of +94.15%. Regarding short-term risk, DMIIR is more volatile compared to RILYM. This indicates higher risk in terms of short-term price fluctuations for DMIIR.Check RILYM's competition here
Drugs Made In America Acquisition II Corp. Unit (NASDAQ: DMIIU)
DMIIR vs DMIIU Comparison November 2026
Drugs Made In America Acquisition II Corp. (NASDAQ: DMIIR) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMIIR stands at 3.2M. In comparison, DMIIU has a market cap of 651.3M. Regarding current trading prices, DMIIR is priced at $0.05 on the NASDAQ, while DMIIU trades at $10.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMIIR currently has a P/E ratio of 0.25, whereas DMIIU's P/E ratio is 50.25. In terms of profitability, DMIIR's ROE is +0.03%, compared to DMIIU's ROE of +0.03%. Regarding short-term risk, DMIIR is more volatile compared to DMIIU. This indicates higher risk in terms of short-term price fluctuations for DMIIR.Check DMIIU's competition here
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII)
DMIIR vs DMII Comparison November 2026
Drugs Made In America Acquisition II Corp. (NASDAQ: DMIIR) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMIIR stands at 3.2M. In comparison, DMII has a market cap of 650.4M. Regarding current trading prices, DMIIR is priced at $0.05 on the NASDAQ, while DMII trades at $10.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMIIR currently has a P/E ratio of 0.25, whereas DMII's P/E ratio is 72.93. In terms of profitability, DMIIR's ROE is +0.03%, compared to DMII's ROE of +0.03%. Regarding short-term risk, DMIIR is more volatile compared to DMII. This indicates higher risk in terms of short-term price fluctuations for DMIIR.Check DMII's competition here
B. Riley Financial, Inc. - 6.75 (NASDAQ: RILYO)
DMIIR vs RILYO Comparison November 2026
Drugs Made In America Acquisition II Corp. (NASDAQ: DMIIR) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMIIR stands at 3.2M. In comparison, RILYO has a market cap of 573.5M. Regarding current trading prices, DMIIR is priced at $0.05 on the NASDAQ, while RILYO trades at $25.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMIIR currently has a P/E ratio of 0.25, whereas RILYO's P/E ratio is N/A. In terms of profitability, DMIIR's ROE is +0.03%, compared to RILYO's ROE of +94.15%. Regarding short-term risk, DMIIR is more volatile compared to RILYO. This indicates higher risk in terms of short-term price fluctuations for DMIIR.Check RILYO's competition here
Voyager Acquisition Corp. (NASDAQ: VACHU)
DMIIR vs VACHU Comparison November 2026
Drugs Made In America Acquisition II Corp. (NASDAQ: DMIIR) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMIIR stands at 3.2M. In comparison, VACHU has a market cap of 475.5M. Regarding current trading prices, DMIIR is priced at $0.05 on the NASDAQ, while VACHU trades at $14.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMIIR currently has a P/E ratio of 0.25, whereas VACHU's P/E ratio is N/A. In terms of profitability, DMIIR's ROE is +0.03%, compared to VACHU's ROE of +0.04%. Regarding short-term risk, DMIIR is more volatile compared to VACHU. This indicates higher risk in terms of short-term price fluctuations for DMIIR.Check VACHU's competition here
Legato Merger Corp. III (AMEX: LEGT-UN)
DMIIR vs LEGT-UN Comparison November 2026
Drugs Made In America Acquisition II Corp. (NASDAQ: DMIIR) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMIIR stands at 3.2M. In comparison, LEGT-UN has a market cap of 467.4M. Regarding current trading prices, DMIIR is priced at $0.05 on the NASDAQ, while LEGT-UN trades at $18.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMIIR currently has a P/E ratio of 0.25, whereas LEGT-UN's P/E ratio is N/A. In terms of profitability, DMIIR's ROE is +0.03%, compared to LEGT-UN's ROE of +0.04%. Regarding short-term risk, DMIIR is less volatile compared to LEGT-UN. This indicates lower risk in terms of short-term price fluctuations for DMIIR.Check LEGT-UN's competition here
Evernorth Holdings Inc. Wt (NASDAQ: XRPNW)
DMIIR vs XRPNW Comparison November 2026
Drugs Made In America Acquisition II Corp. (NASDAQ: DMIIR) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMIIR stands at 3.2M. In comparison, XRPNW has a market cap of 400.1M. Regarding current trading prices, DMIIR is priced at $0.05 on the NASDAQ, while XRPNW trades at $1.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMIIR currently has a P/E ratio of 0.25, whereas XRPNW's P/E ratio is 18.75. In terms of profitability, DMIIR's ROE is +0.03%, compared to XRPNW's ROE of -0.24%. Regarding short-term risk, DMIIR is less volatile compared to XRPNW. This indicates lower risk in terms of short-term price fluctuations for DMIIR.Check XRPNW's competition here
Evernorth Holdings, Inc. Class A (NASDAQ: XRPN)
DMIIR vs XRPN Comparison November 2026
Drugs Made In America Acquisition II Corp. (NASDAQ: DMIIR) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMIIR stands at 3.2M. In comparison, XRPN has a market cap of 370.5M. Regarding current trading prices, DMIIR is priced at $0.05 on the NASDAQ, while XRPN trades at $10.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMIIR currently has a P/E ratio of 0.25, whereas XRPN's P/E ratio is 108.04. In terms of profitability, DMIIR's ROE is +0.03%, compared to XRPN's ROE of -0.24%. Regarding short-term risk, DMIIR is less volatile compared to XRPN. This indicates lower risk in terms of short-term price fluctuations for DMIIR.Check XRPN's competition here
Teamshares Inc. (NASDAQ: TMS)
DMIIR vs TMS Comparison November 2026
Drugs Made In America Acquisition II Corp. (NASDAQ: DMIIR) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMIIR stands at 3.2M. In comparison, TMS has a market cap of 358.5M. Regarding current trading prices, DMIIR is priced at $0.05 on the NASDAQ, while TMS trades at $4.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMIIR currently has a P/E ratio of 0.25, whereas TMS's P/E ratio is N/A. In terms of profitability, DMIIR's ROE is +0.03%, compared to TMS's ROE of N/A. Regarding short-term risk, DMIIR is less volatile compared to TMS. This indicates lower risk in terms of short-term price fluctuations for DMIIR.Check TMS's competition here
DeFi Development Corp. (NASDAQ: CHAD)
DMIIR vs CHAD Comparison November 2026
Drugs Made In America Acquisition II Corp. (NASDAQ: DMIIR) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMIIR stands at 3.2M. In comparison, CHAD has a market cap of 324.9M. Regarding current trading prices, DMIIR is priced at $0.05 on the NASDAQ, while CHAD trades at $9.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMIIR currently has a P/E ratio of 0.25, whereas CHAD's P/E ratio is -1.51. In terms of profitability, DMIIR's ROE is +0.03%, compared to CHAD's ROE of +0.00%. Regarding short-term risk, DMIIR is less volatile compared to CHAD. This indicates lower risk in terms of short-term price fluctuations for DMIIR.Check CHAD's competition here
Safeguard Acquisition Corp. (NYSE: SAC)
DMIIR vs SAC Comparison November 2026
Drugs Made In America Acquisition II Corp. (NASDAQ: DMIIR) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMIIR stands at 3.2M. In comparison, SAC has a market cap of 317.4M. Regarding current trading prices, DMIIR is priced at $0.05 on the NASDAQ, while SAC trades at $10.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMIIR currently has a P/E ratio of 0.25, whereas SAC's P/E ratio is 80.13. In terms of profitability, DMIIR's ROE is +0.03%, compared to SAC's ROE of -0.52%. Regarding short-term risk, DMIIR is more volatile compared to SAC. This indicates higher risk in terms of short-term price fluctuations for DMIIR.Check SAC's competition here
Velos Acquisition I Corp. (NASDAQ: VLOS)
DMIIR vs VLOS Comparison November 2026
Drugs Made In America Acquisition II Corp. (NASDAQ: DMIIR) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMIIR stands at 3.2M. In comparison, VLOS has a market cap of 311.1M. Regarding current trading prices, DMIIR is priced at $0.05 on the NASDAQ, while VLOS trades at $10.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMIIR currently has a P/E ratio of 0.25, whereas VLOS's P/E ratio is 95.67. In terms of profitability, DMIIR's ROE is +0.03%, compared to VLOS's ROE of N/A. Regarding short-term risk, DMIIR is more volatile compared to VLOS. This indicates higher risk in terms of short-term price fluctuations for DMIIR.Check VLOS's competition here
Velos Acquisition I Corp. Units Cons of 1 Sh + 1/2 Red Wt (NASDAQ: VLOSU)
DMIIR vs VLOSU Comparison November 2026
Drugs Made In America Acquisition II Corp. (NASDAQ: DMIIR) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMIIR stands at 3.2M. In comparison, VLOSU has a market cap of 310.8M. Regarding current trading prices, DMIIR is priced at $0.05 on the NASDAQ, while VLOSU trades at $10.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMIIR currently has a P/E ratio of 0.25, whereas VLOSU's P/E ratio is 95.58. In terms of profitability, DMIIR's ROE is +0.03%, compared to VLOSU's ROE of N/A. Regarding short-term risk, DMIIR is more volatile compared to VLOSU. This indicates higher risk in terms of short-term price fluctuations for DMIIR.Check VLOSU's competition here
BRC Group Holdings, Inc. 6.50% Senior Notes Due 2026 (NASDAQ: RILYN)
DMIIR vs RILYN Comparison November 2026
Drugs Made In America Acquisition II Corp. (NASDAQ: DMIIR) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMIIR stands at 3.2M. In comparison, RILYN has a market cap of 295.7M. Regarding current trading prices, DMIIR is priced at $0.05 on the NASDAQ, while RILYN trades at $25.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMIIR currently has a P/E ratio of 0.25, whereas RILYN's P/E ratio is 2.30. In terms of profitability, DMIIR's ROE is +0.03%, compared to RILYN's ROE of +94.15%. Regarding short-term risk, DMIIR is more volatile compared to RILYN. This indicates higher risk in terms of short-term price fluctuations for DMIIR.Check RILYN's competition here
Cantor Equity Partners II, Inc. (NASDAQ: CEPT)
DMIIR vs CEPT Comparison November 2026
Drugs Made In America Acquisition II Corp. (NASDAQ: DMIIR) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMIIR stands at 3.2M. In comparison, CEPT has a market cap of 289.6M. Regarding current trading prices, DMIIR is priced at $0.05 on the NASDAQ, while CEPT trades at $11.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMIIR currently has a P/E ratio of 0.25, whereas CEPT's P/E ratio is -107.09. In terms of profitability, DMIIR's ROE is +0.03%, compared to CEPT's ROE of +0.01%. Regarding short-term risk, DMIIR is less volatile compared to CEPT. This indicates lower risk in terms of short-term price fluctuations for DMIIR.Check CEPT's competition here
NewHold Investment Corp IV Class A Ordinary Shares (NASDAQ: NHIV)
DMIIR vs NHIV Comparison November 2026
Drugs Made In America Acquisition II Corp. (NASDAQ: DMIIR) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMIIR stands at 3.2M. In comparison, NHIV has a market cap of 274.5M. Regarding current trading prices, DMIIR is priced at $0.05 on the NASDAQ, while NHIV trades at $10.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMIIR currently has a P/E ratio of 0.25, whereas NHIV's P/E ratio is N/A. In terms of profitability, DMIIR's ROE is +0.03%, compared to NHIV's ROE of N/A. Regarding short-term risk, DMIIR is more volatile compared to NHIV. This indicates higher risk in terms of short-term price fluctuations for DMIIR.Check NHIV's competition here
Mountain Lake Acquisition Corp. II Class A Ordinary Shares (NASDAQ: MLAA)
DMIIR vs MLAA Comparison November 2026
Drugs Made In America Acquisition II Corp. (NASDAQ: DMIIR) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMIIR stands at 3.2M. In comparison, MLAA has a market cap of 261.5M. Regarding current trading prices, DMIIR is priced at $0.05 on the NASDAQ, while MLAA trades at $10.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMIIR currently has a P/E ratio of 0.25, whereas MLAA's P/E ratio is N/A. In terms of profitability, DMIIR's ROE is +0.03%, compared to MLAA's ROE of N/A. Regarding short-term risk, DMIIR is more volatile compared to MLAA. This indicates higher risk in terms of short-term price fluctuations for DMIIR.Check MLAA's competition here
Keystone Acquisition Corp. Unit (NASDAQ: KEYYU)
DMIIR vs KEYYU Comparison November 2026
Drugs Made In America Acquisition II Corp. (NASDAQ: DMIIR) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMIIR stands at 3.2M. In comparison, KEYYU has a market cap of 254.8M. Regarding current trading prices, DMIIR is priced at $0.05 on the NASDAQ, while KEYYU trades at $10.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMIIR currently has a P/E ratio of 0.25, whereas KEYYU's P/E ratio is N/A. In terms of profitability, DMIIR's ROE is +0.03%, compared to KEYYU's ROE of N/A. Regarding short-term risk, DMIIR is less volatile compared to KEYYU. This indicates lower risk in terms of short-term price fluctuations for DMIIR.Check KEYYU's competition here
OneIM Acquisition Corp. Warrant (NASDAQ: OIMAW)
DMIIR vs OIMAW Comparison November 2026
Drugs Made In America Acquisition II Corp. (NASDAQ: DMIIR) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMIIR stands at 3.2M. In comparison, OIMAW has a market cap of 250M. Regarding current trading prices, DMIIR is priced at $0.05 on the NASDAQ, while OIMAW trades at $0.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMIIR currently has a P/E ratio of 0.25, whereas OIMAW's P/E ratio is -437.50. In terms of profitability, DMIIR's ROE is +0.03%, compared to OIMAW's ROE of N/A. Regarding short-term risk, DMIIR is less volatile compared to OIMAW. This indicates lower risk in terms of short-term price fluctuations for DMIIR.Check OIMAW's competition here
Roman DBDR Acquisition Corp. II (NASDAQ: DRDB)
DMIIR vs DRDB Comparison November 2026
Drugs Made In America Acquisition II Corp. (NASDAQ: DMIIR) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMIIR stands at 3.2M. In comparison, DRDB has a market cap of 247.7M. Regarding current trading prices, DMIIR is priced at $0.05 on the NASDAQ, while DRDB trades at $10.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMIIR currently has a P/E ratio of 0.25, whereas DRDB's P/E ratio is 60.44. In terms of profitability, DMIIR's ROE is +0.03%, compared to DRDB's ROE of +0.02%. Regarding short-term risk, DMIIR is more volatile compared to DRDB. This indicates higher risk in terms of short-term price fluctuations for DMIIR.Check DRDB's competition here
Roman DBDR Acquisition Corp. II (NASDAQ: DRDBU)
DMIIR vs DRDBU Comparison November 2026
Drugs Made In America Acquisition II Corp. (NASDAQ: DMIIR) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMIIR stands at 3.2M. In comparison, DRDBU has a market cap of 247.5M. Regarding current trading prices, DMIIR is priced at $0.05 on the NASDAQ, while DRDBU trades at $10.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMIIR currently has a P/E ratio of 0.25, whereas DRDBU's P/E ratio is 60.38. In terms of profitability, DMIIR's ROE is +0.03%, compared to DRDBU's ROE of +0.02%. Regarding short-term risk, DMIIR is more volatile compared to DRDBU. This indicates higher risk in terms of short-term price fluctuations for DMIIR.Check DRDBU's competition here
Inflection Point Acquisition Corp. VII (NASDAQ: IPXG)
DMIIR vs IPXG Comparison November 2026
Drugs Made In America Acquisition II Corp. (NASDAQ: DMIIR) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMIIR stands at 3.2M. In comparison, IPXG has a market cap of 241.6M. Regarding current trading prices, DMIIR is priced at $0.05 on the NASDAQ, while IPXG trades at $10.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMIIR currently has a P/E ratio of 0.25, whereas IPXG's P/E ratio is N/A. In terms of profitability, DMIIR's ROE is +0.03%, compared to IPXG's ROE of N/A. Regarding short-term risk, DMIIR is less volatile compared to IPXG. This indicates lower risk in terms of short-term price fluctuations for DMIIR.Check IPXG's competition here
Inflection Point Acquisition Corp. VII Units Cons of 1 Shs A + 1/3 Red Wt (NASDAQ: IPXGU)
DMIIR vs IPXGU Comparison November 2026
Drugs Made In America Acquisition II Corp. (NASDAQ: DMIIR) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMIIR stands at 3.2M. In comparison, IPXGU has a market cap of 239.7M. Regarding current trading prices, DMIIR is priced at $0.05 on the NASDAQ, while IPXGU trades at $10.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMIIR currently has a P/E ratio of 0.25, whereas IPXGU's P/E ratio is N/A. In terms of profitability, DMIIR's ROE is +0.03%, compared to IPXGU's ROE of N/A. Regarding short-term risk, DMIIR is less volatile compared to IPXGU. This indicates lower risk in terms of short-term price fluctuations for DMIIR.Check IPXGU's competition here
Illumination Acquisition Corp I Class A Ordinary Shares (NASDAQ: ILLU)
DMIIR vs ILLU Comparison November 2026
Drugs Made In America Acquisition II Corp. (NASDAQ: DMIIR) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMIIR stands at 3.2M. In comparison, ILLU has a market cap of 236.5M. Regarding current trading prices, DMIIR is priced at $0.05 on the NASDAQ, while ILLU trades at $10.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMIIR currently has a P/E ratio of 0.25, whereas ILLU's P/E ratio is N/A. In terms of profitability, DMIIR's ROE is +0.03%, compared to ILLU's ROE of +0.05%. Regarding short-term risk, DMIIR is similarly volatile compared to ILLU. This indicates similar risk in terms of short-term price fluctuations for DMIIR.Check ILLU's competition here
Illumination Acquisition Corp I (NASDAQ: ILLUU)
DMIIR vs ILLUU Comparison November 2026
Drugs Made In America Acquisition II Corp. (NASDAQ: DMIIR) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMIIR stands at 3.2M. In comparison, ILLUU has a market cap of 236.4M. Regarding current trading prices, DMIIR is priced at $0.05 on the NASDAQ, while ILLUU trades at $10.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMIIR currently has a P/E ratio of 0.25, whereas ILLUU's P/E ratio is N/A. In terms of profitability, DMIIR's ROE is +0.03%, compared to ILLUU's ROE of +0.05%. Regarding short-term risk, DMIIR is more volatile compared to ILLUU. This indicates higher risk in terms of short-term price fluctuations for DMIIR.Check ILLUU's competition here
Bluerock Acquisition Corp. Class A Ordinary Shares (NASDAQ: BLRK)
DMIIR vs BLRK Comparison November 2026
Drugs Made In America Acquisition II Corp. (NASDAQ: DMIIR) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMIIR stands at 3.2M. In comparison, BLRK has a market cap of 232.8M. Regarding current trading prices, DMIIR is priced at $0.05 on the NASDAQ, while BLRK trades at $10.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMIIR currently has a P/E ratio of 0.25, whereas BLRK's P/E ratio is 85.69. In terms of profitability, DMIIR's ROE is +0.03%, compared to BLRK's ROE of N/A. Regarding short-term risk, DMIIR is more volatile compared to BLRK. This indicates higher risk in terms of short-term price fluctuations for DMIIR.Check BLRK's competition here
Viking Acquisition Corp. II (NYSE: VII)
DMIIR vs VII Comparison November 2026
Drugs Made In America Acquisition II Corp. (NASDAQ: DMIIR) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMIIR stands at 3.2M. In comparison, VII has a market cap of 232.3M. Regarding current trading prices, DMIIR is priced at $0.05 on the NASDAQ, while VII trades at $9.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMIIR currently has a P/E ratio of 0.25, whereas VII's P/E ratio is N/A. In terms of profitability, DMIIR's ROE is +0.03%, compared to VII's ROE of +0.00%. Regarding short-term risk, DMIIR is more volatile compared to VII. This indicates higher risk in terms of short-term price fluctuations for DMIIR.Check VII's competition here
TRG Latin America Acquisitions Corp. (NASDAQ: TRGSU)
DMIIR vs TRGSU Comparison November 2026
Drugs Made In America Acquisition II Corp. (NASDAQ: DMIIR) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMIIR stands at 3.2M. In comparison, TRGSU has a market cap of 216.1M. Regarding current trading prices, DMIIR is priced at $0.05 on the NASDAQ, while TRGSU trades at $10.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMIIR currently has a P/E ratio of 0.25, whereas TRGSU's P/E ratio is N/A. In terms of profitability, DMIIR's ROE is +0.03%, compared to TRGSU's ROE of N/A. Regarding short-term risk, DMIIR is less volatile compared to TRGSU. This indicates lower risk in terms of short-term price fluctuations for DMIIR.Check TRGSU's competition here
Legato Merger Corp. III (AMEX: LEGT)
DMIIR vs LEGT Comparison November 2026
Drugs Made In America Acquisition II Corp. (NASDAQ: DMIIR) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMIIR stands at 3.2M. In comparison, LEGT has a market cap of 214.8M. Regarding current trading prices, DMIIR is priced at $0.05 on the NASDAQ, while LEGT trades at $9.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMIIR currently has a P/E ratio of 0.25, whereas LEGT's P/E ratio is 32.83. In terms of profitability, DMIIR's ROE is +0.03%, compared to LEGT's ROE of +0.04%. Regarding short-term risk, DMIIR is less volatile compared to LEGT. This indicates lower risk in terms of short-term price fluctuations for DMIIR.Check LEGT's competition here
NewHold Investment Corp IV (NASDAQ: NHIVU)
DMIIR vs NHIVU Comparison November 2026
Drugs Made In America Acquisition II Corp. (NASDAQ: DMIIR) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMIIR stands at 3.2M. In comparison, NHIVU has a market cap of 214.3M. Regarding current trading prices, DMIIR is priced at $0.05 on the NASDAQ, while NHIVU trades at $10.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMIIR currently has a P/E ratio of 0.25, whereas NHIVU's P/E ratio is N/A. In terms of profitability, DMIIR's ROE is +0.03%, compared to NHIVU's ROE of N/A. Regarding short-term risk, DMIIR is more volatile compared to NHIVU. This indicates higher risk in terms of short-term price fluctuations for DMIIR.Check NHIVU's competition here
Quantum Leap Acquisition Corp (NYSE: QLEP)
DMIIR vs QLEP Comparison November 2026
Drugs Made In America Acquisition II Corp. (NASDAQ: DMIIR) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMIIR stands at 3.2M. In comparison, QLEP has a market cap of 212.3M. Regarding current trading prices, DMIIR is priced at $0.05 on the NASDAQ, while QLEP trades at $10.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMIIR currently has a P/E ratio of 0.25, whereas QLEP's P/E ratio is N/A. In terms of profitability, DMIIR's ROE is +0.03%, compared to QLEP's ROE of N/A. Regarding short-term risk, DMIIR is more volatile compared to QLEP. This indicates higher risk in terms of short-term price fluctuations for DMIIR.Check QLEP's competition here
Jones Ventures INTL Acquisition1 Corp (NASDAQ: JONEU)
DMIIR vs JONEU Comparison November 2026
Drugs Made In America Acquisition II Corp. (NASDAQ: DMIIR) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMIIR stands at 3.2M. In comparison, JONEU has a market cap of 209.8M. Regarding current trading prices, DMIIR is priced at $0.05 on the NASDAQ, while JONEU trades at $9.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMIIR currently has a P/E ratio of 0.25, whereas JONEU's P/E ratio is N/A. In terms of profitability, DMIIR's ROE is +0.03%, compared to JONEU's ROE of +7.88%. Regarding short-term risk, DMIIR is more volatile compared to JONEU. This indicates higher risk in terms of short-term price fluctuations for DMIIR.Check JONEU's competition here
Jones Ventures Intl Acquisition1 (NASDAQ: JONE)
DMIIR vs JONE Comparison November 2026
Drugs Made In America Acquisition II Corp. (NASDAQ: DMIIR) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMIIR stands at 3.2M. In comparison, JONE has a market cap of 208.7M. Regarding current trading prices, DMIIR is priced at $0.05 on the NASDAQ, while JONE trades at $9.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMIIR currently has a P/E ratio of 0.25, whereas JONE's P/E ratio is N/A. In terms of profitability, DMIIR's ROE is +0.03%, compared to JONE's ROE of +7.88%. Regarding short-term risk, DMIIR is more volatile compared to JONE. This indicates higher risk in terms of short-term price fluctuations for DMIIR.Check JONE's competition here
Safeguard Acquisition Corp. (NYSE: SAC-UN)
DMIIR vs SAC-UN Comparison November 2026
Drugs Made In America Acquisition II Corp. (NASDAQ: DMIIR) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMIIR stands at 3.2M. In comparison, SAC-UN has a market cap of 208M. Regarding current trading prices, DMIIR is priced at $0.05 on the NASDAQ, while SAC-UN trades at $10.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMIIR currently has a P/E ratio of 0.25, whereas SAC-UN's P/E ratio is 981.13. In terms of profitability, DMIIR's ROE is +0.03%, compared to SAC-UN's ROE of -0.52%. Regarding short-term risk, DMIIR is more volatile compared to SAC-UN. This indicates higher risk in terms of short-term price fluctuations for DMIIR.Check SAC-UN's competition here
TRG Latin America Acquisitions Corp. Class A Ordinary Shares (NASDAQ: TRGS)
DMIIR vs TRGS Comparison November 2026
Drugs Made In America Acquisition II Corp. (NASDAQ: DMIIR) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMIIR stands at 3.2M. In comparison, TRGS has a market cap of 207.9M. Regarding current trading prices, DMIIR is priced at $0.05 on the NASDAQ, while TRGS trades at $9.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMIIR currently has a P/E ratio of 0.25, whereas TRGS's P/E ratio is N/A. In terms of profitability, DMIIR's ROE is +0.03%, compared to TRGS's ROE of N/A. Regarding short-term risk, DMIIR is less volatile compared to TRGS. This indicates lower risk in terms of short-term price fluctuations for DMIIR.Check TRGS's competition here
InterPrivate Investment Partners V, Inc. Units (NASDAQ: IPVVU)
DMIIR vs IPVVU Comparison November 2026
Drugs Made In America Acquisition II Corp. (NASDAQ: DMIIR) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMIIR stands at 3.2M. In comparison, IPVVU has a market cap of 207.5M. Regarding current trading prices, DMIIR is priced at $0.05 on the NASDAQ, while IPVVU trades at $10.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMIIR currently has a P/E ratio of 0.25, whereas IPVVU's P/E ratio is N/A. In terms of profitability, DMIIR's ROE is +0.03%, compared to IPVVU's ROE of N/A. Regarding short-term risk, DMIIR is more volatile compared to IPVVU. This indicates higher risk in terms of short-term price fluctuations for DMIIR.Check IPVVU's competition here
Vendome Acquisition Corporation I (NASDAQ: VNME)
DMIIR vs VNME Comparison November 2026
Drugs Made In America Acquisition II Corp. (NASDAQ: DMIIR) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMIIR stands at 3.2M. In comparison, VNME has a market cap of 207M. Regarding current trading prices, DMIIR is priced at $0.05 on the NASDAQ, while VNME trades at $10.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMIIR currently has a P/E ratio of 0.25, whereas VNME's P/E ratio is 36.66. In terms of profitability, DMIIR's ROE is +0.03%, compared to VNME's ROE of +18.81%. Regarding short-term risk, DMIIR is more volatile compared to VNME. This indicates higher risk in terms of short-term price fluctuations for DMIIR.Check VNME's competition here
Vendome Acquisition Corporation I Warrant (NASDAQ: VNMEW)
DMIIR vs VNMEW Comparison November 2026
Drugs Made In America Acquisition II Corp. (NASDAQ: DMIIR) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMIIR stands at 3.2M. In comparison, VNMEW has a market cap of 206M. Regarding current trading prices, DMIIR is priced at $0.05 on the NASDAQ, while VNMEW trades at $0.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMIIR currently has a P/E ratio of 0.25, whereas VNMEW's P/E ratio is 0.71. In terms of profitability, DMIIR's ROE is +0.03%, compared to VNMEW's ROE of +18.81%. Regarding short-term risk, DMIIR is less volatile compared to VNMEW. This indicates lower risk in terms of short-term price fluctuations for DMIIR.Check VNMEW's competition here
Vendome Acquisition Corporation I Unit (NASDAQ: VNMEU)
DMIIR vs VNMEU Comparison November 2026
Drugs Made In America Acquisition II Corp. (NASDAQ: DMIIR) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMIIR stands at 3.2M. In comparison, VNMEU has a market cap of 206M. Regarding current trading prices, DMIIR is priced at $0.05 on the NASDAQ, while VNMEU trades at $10.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMIIR currently has a P/E ratio of 0.25, whereas VNMEU's P/E ratio is 66.54. In terms of profitability, DMIIR's ROE is +0.03%, compared to VNMEU's ROE of +18.81%. Regarding short-term risk, DMIIR is more volatile compared to VNMEU. This indicates higher risk in terms of short-term price fluctuations for DMIIR.Check VNMEU's competition here
Xterax Corporation II (NASDAQ: XTERU)
DMIIR vs XTERU Comparison November 2026
Drugs Made In America Acquisition II Corp. (NASDAQ: DMIIR) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMIIR stands at 3.2M. In comparison, XTERU has a market cap of 204.2M. Regarding current trading prices, DMIIR is priced at $0.05 on the NASDAQ, while XTERU trades at $9.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMIIR currently has a P/E ratio of 0.25, whereas XTERU's P/E ratio is N/A. In terms of profitability, DMIIR's ROE is +0.03%, compared to XTERU's ROE of N/A. Regarding short-term risk, DMIIR is more volatile compared to XTERU. This indicates higher risk in terms of short-term price fluctuations for DMIIR.Check XTERU's competition here
Interprivate Investment Partners V Inc. (NASDAQ: IPVV)
DMIIR vs IPVV Comparison November 2026
Drugs Made In America Acquisition II Corp. (NASDAQ: DMIIR) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMIIR stands at 3.2M. In comparison, IPVV has a market cap of 203.3M. Regarding current trading prices, DMIIR is priced at $0.05 on the NASDAQ, while IPVV trades at $9.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMIIR currently has a P/E ratio of 0.25, whereas IPVV's P/E ratio is N/A. In terms of profitability, DMIIR's ROE is +0.03%, compared to IPVV's ROE of N/A. Regarding short-term risk, DMIIR is less volatile compared to IPVV. This indicates lower risk in terms of short-term price fluctuations for DMIIR.Check IPVV's competition here
Xterax Corporation II (NASDAQ: XTER)
DMIIR vs XTER Comparison November 2026
Drugs Made In America Acquisition II Corp. (NASDAQ: DMIIR) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMIIR stands at 3.2M. In comparison, XTER has a market cap of 202M. Regarding current trading prices, DMIIR is priced at $0.05 on the NASDAQ, while XTER trades at $9.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMIIR currently has a P/E ratio of 0.25, whereas XTER's P/E ratio is N/A. In terms of profitability, DMIIR's ROE is +0.03%, compared to XTER's ROE of N/A. Regarding short-term risk, DMIIR is more volatile compared to XTER. This indicates higher risk in terms of short-term price fluctuations for DMIIR.Check XTER's competition here
QDRO Acquisition Corp. Units (NASDAQ: QADRU)
DMIIR vs QADRU Comparison November 2026
Drugs Made In America Acquisition II Corp. (NASDAQ: DMIIR) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMIIR stands at 3.2M. In comparison, QADRU has a market cap of 201M. Regarding current trading prices, DMIIR is priced at $0.05 on the NASDAQ, while QADRU trades at $10.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMIIR currently has a P/E ratio of 0.25, whereas QADRU's P/E ratio is N/A. In terms of profitability, DMIIR's ROE is +0.03%, compared to QADRU's ROE of N/A. Regarding short-term risk, DMIIR is less volatile compared to QADRU. This indicates lower risk in terms of short-term price fluctuations for DMIIR.Check QADRU's competition here
QDRO Acquisition Corp. Class A Ordinary Shares (NASDAQ: QADR)
DMIIR vs QADR Comparison November 2026
Drugs Made In America Acquisition II Corp. (NASDAQ: DMIIR) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMIIR stands at 3.2M. In comparison, QADR has a market cap of 200.4M. Regarding current trading prices, DMIIR is priced at $0.05 on the NASDAQ, while QADR trades at $10.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMIIR currently has a P/E ratio of 0.25, whereas QADR's P/E ratio is 292.98. In terms of profitability, DMIIR's ROE is +0.03%, compared to QADR's ROE of N/A. Regarding short-term risk, DMIIR is similarly volatile compared to QADR. This indicates similar risk in terms of short-term price fluctuations for DMIIR.Check QADR's competition here
Meridian3 Ind S Acquisition Corp. (NASDAQ: MIAC)
DMIIR vs MIAC Comparison November 2026
Drugs Made In America Acquisition II Corp. (NASDAQ: DMIIR) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMIIR stands at 3.2M. In comparison, MIAC has a market cap of 199.6M. Regarding current trading prices, DMIIR is priced at $0.05 on the NASDAQ, while MIAC trades at $9.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMIIR currently has a P/E ratio of 0.25, whereas MIAC's P/E ratio is N/A. In terms of profitability, DMIIR's ROE is +0.03%, compared to MIAC's ROE of N/A. Regarding short-term risk, DMIIR is less volatile compared to MIAC. This indicates lower risk in terms of short-term price fluctuations for DMIIR.Check MIAC's competition here
Oceanhawk Acquisition Corp. Class A Ordinary Shares (NASDAQ: OHAC)
DMIIR vs OHAC Comparison November 2026
Drugs Made In America Acquisition II Corp. (NASDAQ: DMIIR) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMIIR stands at 3.2M. In comparison, OHAC has a market cap of 189.7M. Regarding current trading prices, DMIIR is priced at $0.05 on the NASDAQ, while OHAC trades at $10.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMIIR currently has a P/E ratio of 0.25, whereas OHAC's P/E ratio is N/A. In terms of profitability, DMIIR's ROE is +0.03%, compared to OHAC's ROE of N/A. Regarding short-term risk, DMIIR is more volatile compared to OHAC. This indicates higher risk in terms of short-term price fluctuations for DMIIR.Check OHAC's competition here
Oceanhawk Acquisition Corp. Rights (NASDAQ: OHACR)
DMIIR vs OHACR Comparison November 2026
Drugs Made In America Acquisition II Corp. (NASDAQ: DMIIR) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMIIR stands at 3.2M. In comparison, OHACR has a market cap of 189.3M. Regarding current trading prices, DMIIR is priced at $0.05 on the NASDAQ, while OHACR trades at $0.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMIIR currently has a P/E ratio of 0.25, whereas OHACR's P/E ratio is N/A. In terms of profitability, DMIIR's ROE is +0.03%, compared to OHACR's ROE of N/A. Regarding short-term risk, DMIIR is less volatile compared to OHACR. This indicates lower risk in terms of short-term price fluctuations for DMIIR.Check OHACR's competition here
JAB Acquisition Corp. I Class A (NASDAQ: ATLQ)
DMIIR vs ATLQ Comparison November 2026
Drugs Made In America Acquisition II Corp. (NASDAQ: DMIIR) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMIIR stands at 3.2M. In comparison, ATLQ has a market cap of 186.4M. Regarding current trading prices, DMIIR is priced at $0.05 on the NASDAQ, while ATLQ trades at $10.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMIIR currently has a P/E ratio of 0.25, whereas ATLQ's P/E ratio is N/A. In terms of profitability, DMIIR's ROE is +0.03%, compared to ATLQ's ROE of N/A. Regarding short-term risk, DMIIR is more volatile compared to ATLQ. This indicates higher risk in terms of short-term price fluctuations for DMIIR.Check ATLQ's competition here
Dynamix Corporation (NASDAQ: ETHM)
DMIIR vs ETHM Comparison November 2026
Drugs Made In America Acquisition II Corp. (NASDAQ: DMIIR) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMIIR stands at 3.2M. In comparison, ETHM has a market cap of 182.1M. Regarding current trading prices, DMIIR is priced at $0.05 on the NASDAQ, while ETHM trades at $10.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMIIR currently has a P/E ratio of 0.25, whereas ETHM's P/E ratio is -13.71. In terms of profitability, DMIIR's ROE is +0.03%, compared to ETHM's ROE of +0.62%. Regarding short-term risk, DMIIR is less volatile compared to ETHM. This indicates lower risk in terms of short-term price fluctuations for DMIIR.Check ETHM's competition here
Roman DBDR Acquisition Corp. II (NASDAQ: DRDBW)
DMIIR vs DRDBW Comparison November 2026
Drugs Made In America Acquisition II Corp. (NASDAQ: DMIIR) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMIIR stands at 3.2M. In comparison, DRDBW has a market cap of 179.9M. Regarding current trading prices, DMIIR is priced at $0.05 on the NASDAQ, while DRDBW trades at $0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMIIR currently has a P/E ratio of 0.25, whereas DRDBW's P/E ratio is 0.40. In terms of profitability, DMIIR's ROE is +0.03%, compared to DRDBW's ROE of +0.02%. Regarding short-term risk, DMIIR is less volatile compared to DRDBW. This indicates lower risk in terms of short-term price fluctuations for DMIIR.Check DRDBW's competition here
Breeze Acquisition Corp. II (NASDAQ: BREZ)
DMIIR vs BREZ Comparison November 2026
Drugs Made In America Acquisition II Corp. (NASDAQ: DMIIR) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMIIR stands at 3.2M. In comparison, BREZ has a market cap of 179M. Regarding current trading prices, DMIIR is priced at $0.05 on the NASDAQ, while BREZ trades at $10.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMIIR currently has a P/E ratio of 0.25, whereas BREZ's P/E ratio is 1659.02. In terms of profitability, DMIIR's ROE is +0.03%, compared to BREZ's ROE of +0.53%. Regarding short-term risk, DMIIR is less volatile compared to BREZ. This indicates lower risk in terms of short-term price fluctuations for DMIIR.Check BREZ's competition here
JAB Acquisition Corp. I Units Cons of 1 Sh -A- + 1 Red Wt + 1 Rt (NASDAQ: ATLQU)
DMIIR vs ATLQU Comparison November 2026
Drugs Made In America Acquisition II Corp. (NASDAQ: DMIIR) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMIIR stands at 3.2M. In comparison, ATLQU has a market cap of 177.6M. Regarding current trading prices, DMIIR is priced at $0.05 on the NASDAQ, while ATLQU trades at $10.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMIIR currently has a P/E ratio of 0.25, whereas ATLQU's P/E ratio is N/A. In terms of profitability, DMIIR's ROE is +0.03%, compared to ATLQU's ROE of N/A. Regarding short-term risk, DMIIR is more volatile compared to ATLQU. This indicates higher risk in terms of short-term price fluctuations for DMIIR.Check ATLQU's competition here
Bluerock Acquisition Corp. (NASDAQ: BLRKU)
DMIIR vs BLRKU Comparison November 2026
Drugs Made In America Acquisition II Corp. (NASDAQ: DMIIR) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMIIR stands at 3.2M. In comparison, BLRKU has a market cap of 175.6M. Regarding current trading prices, DMIIR is priced at $0.05 on the NASDAQ, while BLRKU trades at $10.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMIIR currently has a P/E ratio of 0.25, whereas BLRKU's P/E ratio is N/A. In terms of profitability, DMIIR's ROE is +0.03%, compared to BLRKU's ROE of N/A. Regarding short-term risk, DMIIR is less volatile compared to BLRKU. This indicates lower risk in terms of short-term price fluctuations for DMIIR.Check BLRKU's competition here
Viking Acquisition Corp. I (NYSE: VACI-UN)
DMIIR vs VACI-UN Comparison November 2026
Drugs Made In America Acquisition II Corp. (NASDAQ: DMIIR) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMIIR stands at 3.2M. In comparison, VACI-UN has a market cap of 174.8M. Regarding current trading prices, DMIIR is priced at $0.05 on the NASDAQ, while VACI-UN trades at $7.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMIIR currently has a P/E ratio of 0.25, whereas VACI-UN's P/E ratio is 85.59. In terms of profitability, DMIIR's ROE is +0.03%, compared to VACI-UN's ROE of +0.01%. Regarding short-term risk, DMIIR is more volatile compared to VACI-UN. This indicates higher risk in terms of short-term price fluctuations for DMIIR.Check VACI-UN's competition here
Jab Acquisition Corp. I (NASDAQ: JAB)
DMIIR vs JAB Comparison November 2026
Drugs Made In America Acquisition II Corp. (NASDAQ: DMIIR) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMIIR stands at 3.2M. In comparison, JAB has a market cap of 174.2M. Regarding current trading prices, DMIIR is priced at $0.05 on the NASDAQ, while JAB trades at $9.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMIIR currently has a P/E ratio of 0.25, whereas JAB's P/E ratio is N/A. In terms of profitability, DMIIR's ROE is +0.03%, compared to JAB's ROE of N/A. Regarding short-term risk, DMIIR is similarly volatile compared to JAB. This indicates similar risk in terms of short-term price fluctuations for DMIIR.Check JAB's competition here
Long Table Growth Corp. Units (NASDAQ: LTGRU)
DMIIR vs LTGRU Comparison November 2026
Drugs Made In America Acquisition II Corp. (NASDAQ: DMIIR) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMIIR stands at 3.2M. In comparison, LTGRU has a market cap of 173.5M. Regarding current trading prices, DMIIR is priced at $0.05 on the NASDAQ, while LTGRU trades at $10.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMIIR currently has a P/E ratio of 0.25, whereas LTGRU's P/E ratio is N/A. In terms of profitability, DMIIR's ROE is +0.03%, compared to LTGRU's ROE of N/A. Regarding short-term risk, DMIIR is less volatile compared to LTGRU. This indicates lower risk in terms of short-term price fluctuations for DMIIR.Check LTGRU's competition here
Long Table Growth Corp. (NASDAQ: LTGR)
DMIIR vs LTGR Comparison November 2026
Drugs Made In America Acquisition II Corp. (NASDAQ: DMIIR) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMIIR stands at 3.2M. In comparison, LTGR has a market cap of 172.7M. Regarding current trading prices, DMIIR is priced at $0.05 on the NASDAQ, while LTGR trades at $10.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMIIR currently has a P/E ratio of 0.25, whereas LTGR's P/E ratio is N/A. In terms of profitability, DMIIR's ROE is +0.03%, compared to LTGR's ROE of N/A. Regarding short-term risk, DMIIR is more volatile compared to LTGR. This indicates higher risk in terms of short-term price fluctuations for DMIIR.Check LTGR's competition here
Texas Ventures Acquisition IV Corp. (NASDAQ: TVIV)
DMIIR vs TVIV Comparison November 2026
Drugs Made In America Acquisition II Corp. (NASDAQ: DMIIR) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMIIR stands at 3.2M. In comparison, TVIV has a market cap of 172.3M. Regarding current trading prices, DMIIR is priced at $0.05 on the NASDAQ, while TVIV trades at $9.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMIIR currently has a P/E ratio of 0.25, whereas TVIV's P/E ratio is -5876.47. In terms of profitability, DMIIR's ROE is +0.03%, compared to TVIV's ROE of N/A. Regarding short-term risk, DMIIR is more volatile compared to TVIV. This indicates higher risk in terms of short-term price fluctuations for DMIIR.Check TVIV's competition here
Meridian3 Industrials Aquisition Corp Warrant (NASDAQ: MIACW)
DMIIR vs MIACW Comparison November 2026
Drugs Made In America Acquisition II Corp. (NASDAQ: DMIIR) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMIIR stands at 3.2M. In comparison, MIACW has a market cap of 164.9M. Regarding current trading prices, DMIIR is priced at $0.05 on the NASDAQ, while MIACW trades at $0.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMIIR currently has a P/E ratio of 0.25, whereas MIACW's P/E ratio is N/A. In terms of profitability, DMIIR's ROE is +0.03%, compared to MIACW's ROE of N/A. Regarding short-term risk, DMIIR is less volatile compared to MIACW. This indicates lower risk in terms of short-term price fluctuations for DMIIR.Check MIACW's competition here
Collective Acquisition Corp. (NASDAQ: CCAQU)
DMIIR vs CCAQU Comparison November 2026
Drugs Made In America Acquisition II Corp. (NASDAQ: DMIIR) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMIIR stands at 3.2M. In comparison, CCAQU has a market cap of 157.7M. Regarding current trading prices, DMIIR is priced at $0.05 on the NASDAQ, while CCAQU trades at $10.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMIIR currently has a P/E ratio of 0.25, whereas CCAQU's P/E ratio is 59.81. In terms of profitability, DMIIR's ROE is +0.03%, compared to CCAQU's ROE of +0.03%. Regarding short-term risk, DMIIR is more volatile compared to CCAQU. This indicates higher risk in terms of short-term price fluctuations for DMIIR.Check CCAQU's competition here
Arc Group Securities Acquisition I (NASDAQ: FJDIU)
DMIIR vs FJDIU Comparison November 2026
Drugs Made In America Acquisition II Corp. (NASDAQ: DMIIR) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMIIR stands at 3.2M. In comparison, FJDIU has a market cap of 157.2M. Regarding current trading prices, DMIIR is priced at $0.05 on the NASDAQ, while FJDIU trades at $10.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMIIR currently has a P/E ratio of 0.25, whereas FJDIU's P/E ratio is N/A. In terms of profitability, DMIIR's ROE is +0.03%, compared to FJDIU's ROE of N/A. Regarding short-term risk, DMIIR is more volatile compared to FJDIU. This indicates higher risk in terms of short-term price fluctuations for DMIIR.Check FJDIU's competition here
Ocean Capital Acquisition Corporation (NYSE: OCAC)
DMIIR vs OCAC Comparison November 2026
Drugs Made In America Acquisition II Corp. (NASDAQ: DMIIR) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMIIR stands at 3.2M. In comparison, OCAC has a market cap of 156.8M. Regarding current trading prices, DMIIR is priced at $0.05 on the NASDAQ, while OCAC trades at $10.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMIIR currently has a P/E ratio of 0.25, whereas OCAC's P/E ratio is -692.40. In terms of profitability, DMIIR's ROE is +0.03%, compared to OCAC's ROE of N/A. Regarding short-term risk, DMIIR is more volatile compared to OCAC. This indicates higher risk in terms of short-term price fluctuations for DMIIR.Check OCAC's competition here
Graf Global Corp. (AMEX: TONT)
DMIIR vs TONT Comparison November 2026
Drugs Made In America Acquisition II Corp. (NASDAQ: DMIIR) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMIIR stands at 3.2M. In comparison, TONT has a market cap of 155.3M. Regarding current trading prices, DMIIR is priced at $0.05 on the NASDAQ, while TONT trades at $10.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMIIR currently has a P/E ratio of 0.25, whereas TONT's P/E ratio is 61.43. In terms of profitability, DMIIR's ROE is +0.03%, compared to TONT's ROE of N/A. Regarding short-term risk, DMIIR is more volatile compared to TONT. This indicates higher risk in terms of short-term price fluctuations for DMIIR.Check TONT's competition here
Social Capital Hedosophia Holdings Corp. IV (NASDAQ: IPOD)
DMIIR vs IPOD Comparison November 2026
Drugs Made In America Acquisition II Corp. (NASDAQ: DMIIR) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMIIR stands at 3.2M. In comparison, IPOD has a market cap of 154.4M. Regarding current trading prices, DMIIR is priced at $0.05 on the NASDAQ, while IPOD trades at $10.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMIIR currently has a P/E ratio of 0.25, whereas IPOD's P/E ratio is 58.12. In terms of profitability, DMIIR's ROE is +0.03%, compared to IPOD's ROE of +0.05%. Regarding short-term risk, DMIIR is more volatile compared to IPOD. This indicates higher risk in terms of short-term price fluctuations for DMIIR.Check IPOD's competition here
Black Spade Acquisition II Co (NASDAQ: BSIIU)
DMIIR vs BSIIU Comparison November 2026
Drugs Made In America Acquisition II Corp. (NASDAQ: DMIIR) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMIIR stands at 3.2M. In comparison, BSIIU has a market cap of 152.8M. Regarding current trading prices, DMIIR is priced at $0.05 on the NASDAQ, while BSIIU trades at $9.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMIIR currently has a P/E ratio of 0.25, whereas BSIIU's P/E ratio is N/A. In terms of profitability, DMIIR's ROE is +0.03%, compared to BSIIU's ROE of -266.79%. Regarding short-term risk, DMIIR is more volatile compared to BSIIU. This indicates higher risk in terms of short-term price fluctuations for DMIIR.Check BSIIU's competition here
JAB Acquisition Corp I (NASDAQ: JABRU)
DMIIR vs JABRU Comparison November 2026
Drugs Made In America Acquisition II Corp. (NASDAQ: DMIIR) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMIIR stands at 3.2M. In comparison, JABRU has a market cap of 152.3M. Regarding current trading prices, DMIIR is priced at $0.05 on the NASDAQ, while JABRU trades at $10.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMIIR currently has a P/E ratio of 0.25, whereas JABRU's P/E ratio is N/A. In terms of profitability, DMIIR's ROE is +0.03%, compared to JABRU's ROE of N/A. Regarding short-term risk, DMIIR is more volatile compared to JABRU. This indicates higher risk in terms of short-term price fluctuations for DMIIR.Check JABRU's competition here
Collective Acquisition Corp. (NASDAQ: CCAQ)
DMIIR vs CCAQ Comparison November 2026
Drugs Made In America Acquisition II Corp. (NASDAQ: DMIIR) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMIIR stands at 3.2M. In comparison, CCAQ has a market cap of 151.9M. Regarding current trading prices, DMIIR is priced at $0.05 on the NASDAQ, while CCAQ trades at $10.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMIIR currently has a P/E ratio of 0.25, whereas CCAQ's P/E ratio is 57.20. In terms of profitability, DMIIR's ROE is +0.03%, compared to CCAQ's ROE of +0.03%. Regarding short-term risk, DMIIR is less volatile compared to CCAQ. This indicates lower risk in terms of short-term price fluctuations for DMIIR.Check CCAQ's competition here
SPACCircle Acquisition Corp. (NASDAQ: SCQCU)
DMIIR vs SCQCU Comparison November 2026
Drugs Made In America Acquisition II Corp. (NASDAQ: DMIIR) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMIIR stands at 3.2M. In comparison, SCQCU has a market cap of 150M. Regarding current trading prices, DMIIR is priced at $0.05 on the NASDAQ, while SCQCU trades at $10.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMIIR currently has a P/E ratio of 0.25, whereas SCQCU's P/E ratio is N/A. In terms of profitability, DMIIR's ROE is +0.03%, compared to SCQCU's ROE of N/A. Regarding short-term risk, DMIIR is more volatile compared to SCQCU. This indicates higher risk in terms of short-term price fluctuations for DMIIR.Check SCQCU's competition here
BRC Group Holdings Inc. 5% Sr. Notes due 2026 (NASDAQ: RILYG)
DMIIR vs RILYG Comparison November 2026
Drugs Made In America Acquisition II Corp. (NASDAQ: DMIIR) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMIIR stands at 3.2M. In comparison, RILYG has a market cap of 147.9M. Regarding current trading prices, DMIIR is priced at $0.05 on the NASDAQ, while RILYG trades at $24.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMIIR currently has a P/E ratio of 0.25, whereas RILYG's P/E ratio is 4.67. In terms of profitability, DMIIR's ROE is +0.03%, compared to RILYG's ROE of +94.15%. Regarding short-term risk, DMIIR is less volatile compared to RILYG. This indicates lower risk in terms of short-term price fluctuations for DMIIR.Check RILYG's competition here
BRC Group Holdings, Inc. - Depositary Shares, each representing a 1/1000th fractional interest in a share of Series B Cumulative Perpetual Preferred Stock (NASDAQ: RILYL)
DMIIR vs RILYL Comparison November 2026
Drugs Made In America Acquisition II Corp. (NASDAQ: DMIIR) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMIIR stands at 3.2M. In comparison, RILYL has a market cap of 147.8M. Regarding current trading prices, DMIIR is priced at $0.05 on the NASDAQ, while RILYL trades at $6.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMIIR currently has a P/E ratio of 0.25, whereas RILYL's P/E ratio is 0.46. In terms of profitability, DMIIR's ROE is +0.03%, compared to RILYL's ROE of +94.15%. Regarding short-term risk, DMIIR is less volatile compared to RILYL. This indicates lower risk in terms of short-term price fluctuations for DMIIR.Check RILYL's competition here
B. Riley Financial, Inc. 6.00% Senior Notes Due 2028 (NASDAQ: RILYT)
DMIIR vs RILYT Comparison November 2026
Drugs Made In America Acquisition II Corp. (NASDAQ: DMIIR) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMIIR stands at 3.2M. In comparison, RILYT has a market cap of 147.6M. Regarding current trading prices, DMIIR is priced at $0.05 on the NASDAQ, while RILYT trades at $18.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMIIR currently has a P/E ratio of 0.25, whereas RILYT's P/E ratio is 3.51. In terms of profitability, DMIIR's ROE is +0.03%, compared to RILYT's ROE of +94.15%. Regarding short-term risk, DMIIR is less volatile compared to RILYT. This indicates lower risk in terms of short-term price fluctuations for DMIIR.Check RILYT's competition here
Southern Cross Acquisition I Corp. (NASDAQ: NCO)
DMIIR vs NCO Comparison November 2026
Drugs Made In America Acquisition II Corp. (NASDAQ: DMIIR) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMIIR stands at 3.2M. In comparison, NCO has a market cap of 146.7M. Regarding current trading prices, DMIIR is priced at $0.05 on the NASDAQ, while NCO trades at $9.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMIIR currently has a P/E ratio of 0.25, whereas NCO's P/E ratio is N/A. In terms of profitability, DMIIR's ROE is +0.03%, compared to NCO's ROE of N/A. Regarding short-term risk, DMIIR is more volatile compared to NCO. This indicates higher risk in terms of short-term price fluctuations for DMIIR.Check NCO's competition here
BRC Group Holdings, Inc. (NASDAQ: RILYP)
DMIIR vs RILYP Comparison November 2026
Drugs Made In America Acquisition II Corp. (NASDAQ: DMIIR) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMIIR stands at 3.2M. In comparison, RILYP has a market cap of 146.5M. Regarding current trading prices, DMIIR is priced at $0.05 on the NASDAQ, while RILYP trades at $6.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMIIR currently has a P/E ratio of 0.25, whereas RILYP's P/E ratio is 0.45. In terms of profitability, DMIIR's ROE is +0.03%, compared to RILYP's ROE of +94.15%. Regarding short-term risk, DMIIR is less volatile compared to RILYP. This indicates lower risk in terms of short-term price fluctuations for DMIIR.Check RILYP's competition here
BRC Group Holdings, Inc. (NASDAQ: RILY)
DMIIR vs RILY Comparison November 2026
Drugs Made In America Acquisition II Corp. (NASDAQ: DMIIR) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMIIR stands at 3.2M. In comparison, RILY has a market cap of 146.3M. Regarding current trading prices, DMIIR is priced at $0.05 on the NASDAQ, while RILY trades at $3.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMIIR currently has a P/E ratio of 0.25, whereas RILY's P/E ratio is 0.29. In terms of profitability, DMIIR's ROE is +0.03%, compared to RILY's ROE of +94.15%. Regarding short-term risk, DMIIR is less volatile compared to RILY. This indicates lower risk in terms of short-term price fluctuations for DMIIR.Check RILY's competition here
BRC Group Holdings Inc. 5.25% Sr. Notes due 2028 (NASDAQ: RILYZ)
DMIIR vs RILYZ Comparison November 2026
Drugs Made In America Acquisition II Corp. (NASDAQ: DMIIR) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMIIR stands at 3.2M. In comparison, RILYZ has a market cap of 146M. Regarding current trading prices, DMIIR is priced at $0.05 on the NASDAQ, while RILYZ trades at $16.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMIIR currently has a P/E ratio of 0.25, whereas RILYZ's P/E ratio is 3.06. In terms of profitability, DMIIR's ROE is +0.03%, compared to RILYZ's ROE of +94.15%. Regarding short-term risk, DMIIR is less volatile compared to RILYZ. This indicates lower risk in terms of short-term price fluctuations for DMIIR.Check RILYZ's competition here
Breeze Acquisition Corp. II (NASDAQ: BREZR)
DMIIR vs BREZR Comparison November 2026
Drugs Made In America Acquisition II Corp. (NASDAQ: DMIIR) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMIIR stands at 3.2M. In comparison, BREZR has a market cap of 143.8M. Regarding current trading prices, DMIIR is priced at $0.05 on the NASDAQ, while BREZR trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMIIR currently has a P/E ratio of 0.25, whereas BREZR's P/E ratio is 44.25. In terms of profitability, DMIIR's ROE is +0.03%, compared to BREZR's ROE of +0.53%. Regarding short-term risk, DMIIR is less volatile compared to BREZR. This indicates lower risk in terms of short-term price fluctuations for DMIIR.Check BREZR's competition here
Social Commerce Partners Corporation (NASDAQ: SCPQW)
DMIIR vs SCPQW Comparison November 2026
Drugs Made In America Acquisition II Corp. (NASDAQ: DMIIR) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMIIR stands at 3.2M. In comparison, SCPQW has a market cap of 138.1M. Regarding current trading prices, DMIIR is priced at $0.05 on the NASDAQ, while SCPQW trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMIIR currently has a P/E ratio of 0.25, whereas SCPQW's P/E ratio is 4.92. In terms of profitability, DMIIR's ROE is +0.03%, compared to SCPQW's ROE of N/A. Regarding short-term risk, DMIIR is more volatile compared to SCPQW. This indicates higher risk in terms of short-term price fluctuations for DMIIR.Check SCPQW's competition here
Forefront Tech Holdings Acquisition Corp Unit (NASDAQ: FTHAU)
DMIIR vs FTHAU Comparison November 2026
Drugs Made In America Acquisition II Corp. (NASDAQ: DMIIR) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMIIR stands at 3.2M. In comparison, FTHAU has a market cap of 137.6M. Regarding current trading prices, DMIIR is priced at $0.05 on the NASDAQ, while FTHAU trades at $10.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMIIR currently has a P/E ratio of 0.25, whereas FTHAU's P/E ratio is N/A. In terms of profitability, DMIIR's ROE is +0.03%, compared to FTHAU's ROE of N/A. Regarding short-term risk, DMIIR is more volatile compared to FTHAU. This indicates higher risk in terms of short-term price fluctuations for DMIIR.Check FTHAU's competition here
East West Ave Acquisition Corp. Common Stock (NASDAQ: EWAV)
DMIIR vs EWAV Comparison November 2026
Drugs Made In America Acquisition II Corp. (NASDAQ: DMIIR) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMIIR stands at 3.2M. In comparison, EWAV has a market cap of 127.2M. Regarding current trading prices, DMIIR is priced at $0.05 on the NASDAQ, while EWAV trades at $9.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMIIR currently has a P/E ratio of 0.25, whereas EWAV's P/E ratio is -14142.86. In terms of profitability, DMIIR's ROE is +0.03%, compared to EWAV's ROE of N/A. Regarding short-term risk, DMIIR is less volatile compared to EWAV. This indicates lower risk in terms of short-term price fluctuations for DMIIR.Check EWAV's competition here
Southern Cross Acquisition I Corp. (NASDAQ: NCOOU)
DMIIR vs NCOOU Comparison November 2026
Drugs Made In America Acquisition II Corp. (NASDAQ: DMIIR) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMIIR stands at 3.2M. In comparison, NCOOU has a market cap of 118.2M. Regarding current trading prices, DMIIR is priced at $0.05 on the NASDAQ, while NCOOU trades at $10.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMIIR currently has a P/E ratio of 0.25, whereas NCOOU's P/E ratio is N/A. In terms of profitability, DMIIR's ROE is +0.03%, compared to NCOOU's ROE of N/A. Regarding short-term risk, DMIIR is more volatile compared to NCOOU. This indicates higher risk in terms of short-term price fluctuations for DMIIR.Check NCOOU's competition here
Plutonian Acquisition Corp II (NYSE: PLUN)
DMIIR vs PLUN Comparison November 2026
Drugs Made In America Acquisition II Corp. (NASDAQ: DMIIR) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMIIR stands at 3.2M. In comparison, PLUN has a market cap of 115.7M. Regarding current trading prices, DMIIR is priced at $0.05 on the NASDAQ, while PLUN trades at $10.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMIIR currently has a P/E ratio of 0.25, whereas PLUN's P/E ratio is 338.67. In terms of profitability, DMIIR's ROE is +0.03%, compared to PLUN's ROE of N/A. Regarding short-term risk, DMIIR is more volatile compared to PLUN. This indicates higher risk in terms of short-term price fluctuations for DMIIR.Check PLUN's competition here
Enhanced Group Inc. Class A (NYSE: ENHA)
DMIIR vs ENHA Comparison November 2026
Drugs Made In America Acquisition II Corp. (NASDAQ: DMIIR) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMIIR stands at 3.2M. In comparison, ENHA has a market cap of 113.3M. Regarding current trading prices, DMIIR is priced at $0.05 on the NASDAQ, while ENHA trades at $8.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMIIR currently has a P/E ratio of 0.25, whereas ENHA's P/E ratio is -30.67. In terms of profitability, DMIIR's ROE is +0.03%, compared to ENHA's ROE of -3.98%. Regarding short-term risk, DMIIR is less volatile compared to ENHA. This indicates lower risk in terms of short-term price fluctuations for DMIIR.Check ENHA's competition here
Shepherd Ave Capital Acquisition Corporation (NASDAQ: SPHA)
DMIIR vs SPHA Comparison November 2026
Drugs Made In America Acquisition II Corp. (NASDAQ: DMIIR) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMIIR stands at 3.2M. In comparison, SPHA has a market cap of 111.7M. Regarding current trading prices, DMIIR is priced at $0.05 on the NASDAQ, while SPHA trades at $10.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMIIR currently has a P/E ratio of 0.25, whereas SPHA's P/E ratio is N/A. In terms of profitability, DMIIR's ROE is +0.03%, compared to SPHA's ROE of -1.30%. Regarding short-term risk, DMIIR is less volatile compared to SPHA. This indicates lower risk in terms of short-term price fluctuations for DMIIR.Check SPHA's competition here
Arc Group Securities Acquisition I (NASDAQ: FJDI)
DMIIR vs FJDI Comparison November 2026
Drugs Made In America Acquisition II Corp. (NASDAQ: DMIIR) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMIIR stands at 3.2M. In comparison, FJDI has a market cap of 110.4M. Regarding current trading prices, DMIIR is priced at $0.05 on the NASDAQ, while FJDI trades at $9.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMIIR currently has a P/E ratio of 0.25, whereas FJDI's P/E ratio is N/A. In terms of profitability, DMIIR's ROE is +0.03%, compared to FJDI's ROE of N/A. Regarding short-term risk, DMIIR is less volatile compared to FJDI. This indicates lower risk in terms of short-term price fluctuations for DMIIR.Check FJDI's competition here
Amanat Acquisition Corp Class A Ordinary Shares (NASDAQ: AMAN)
DMIIR vs AMAN Comparison November 2026
Drugs Made In America Acquisition II Corp. (NASDAQ: DMIIR) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMIIR stands at 3.2M. In comparison, AMAN has a market cap of 97.9M. Regarding current trading prices, DMIIR is priced at $0.05 on the NASDAQ, while AMAN trades at $10.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMIIR currently has a P/E ratio of 0.25, whereas AMAN's P/E ratio is N/A. In terms of profitability, DMIIR's ROE is +0.03%, compared to AMAN's ROE of N/A. Regarding short-term risk, DMIIR is more volatile compared to AMAN. This indicates higher risk in terms of short-term price fluctuations for DMIIR.Check AMAN's competition here
Cayson Acquisition Corp (NASDAQ: CAPNU)
DMIIR vs CAPNU Comparison November 2026
Drugs Made In America Acquisition II Corp. (NASDAQ: DMIIR) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMIIR stands at 3.2M. In comparison, CAPNU has a market cap of 94M. Regarding current trading prices, DMIIR is priced at $0.05 on the NASDAQ, while CAPNU trades at $11.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMIIR currently has a P/E ratio of 0.25, whereas CAPNU's P/E ratio is 56.23. In terms of profitability, DMIIR's ROE is +0.03%, compared to CAPNU's ROE of +0.03%. Regarding short-term risk, DMIIR is more volatile compared to CAPNU. This indicates higher risk in terms of short-term price fluctuations for DMIIR.Check CAPNU's competition here
FTAC Emerald Acquisition Corp. (NASDAQ: FLDD)
DMIIR vs FLDD Comparison November 2026
Drugs Made In America Acquisition II Corp. (NASDAQ: DMIIR) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMIIR stands at 3.2M. In comparison, FLDD has a market cap of 85.6M. Regarding current trading prices, DMIIR is priced at $0.05 on the NASDAQ, while FLDD trades at $6.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMIIR currently has a P/E ratio of 0.25, whereas FLDD's P/E ratio is -75.13. In terms of profitability, DMIIR's ROE is +0.03%, compared to FLDD's ROE of N/A. Regarding short-term risk, DMIIR is less volatile compared to FLDD. This indicates lower risk in terms of short-term price fluctuations for DMIIR.Check FLDD's competition here
Research Alliance Corp. Iv (NASDAQ: RACD)
DMIIR vs RACD Comparison November 2026
Drugs Made In America Acquisition II Corp. (NASDAQ: DMIIR) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMIIR stands at 3.2M. In comparison, RACD has a market cap of 80.1M. Regarding current trading prices, DMIIR is priced at $0.05 on the NASDAQ, while RACD trades at $10.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMIIR currently has a P/E ratio of 0.25, whereas RACD's P/E ratio is N/A. In terms of profitability, DMIIR's ROE is +0.03%, compared to RACD's ROE of N/A. Regarding short-term risk, DMIIR is less volatile compared to RACD. This indicates lower risk in terms of short-term price fluctuations for DMIIR.Check RACD's competition here
Armada Acquisition Corp. III (NASDAQ: AACIU)
DMIIR vs AACIU Comparison November 2026
Drugs Made In America Acquisition II Corp. (NASDAQ: DMIIR) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMIIR stands at 3.2M. In comparison, AACIU has a market cap of 72.8M. Regarding current trading prices, DMIIR is priced at $0.05 on the NASDAQ, while AACIU trades at $10.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMIIR currently has a P/E ratio of 0.25, whereas AACIU's P/E ratio is N/A. In terms of profitability, DMIIR's ROE is +0.03%, compared to AACIU's ROE of -0.24%. Regarding short-term risk, DMIIR is more volatile compared to AACIU. This indicates higher risk in terms of short-term price fluctuations for DMIIR.Check AACIU's competition here
Collective Acquisition Corp. (NASDAQ: CCAQW)
DMIIR vs CCAQW Comparison November 2026
Drugs Made In America Acquisition II Corp. (NASDAQ: DMIIR) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMIIR stands at 3.2M. In comparison, CCAQW has a market cap of 66.7M. Regarding current trading prices, DMIIR is priced at $0.05 on the NASDAQ, while CCAQW trades at $0.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMIIR currently has a P/E ratio of 0.25, whereas CCAQW's P/E ratio is 0.66. In terms of profitability, DMIIR's ROE is +0.03%, compared to CCAQW's ROE of +0.03%. Regarding short-term risk, DMIIR is less volatile compared to CCAQW. This indicates lower risk in terms of short-term price fluctuations for DMIIR.Check CCAQW's competition here
Bayview Acquisition Corp Unit (NASDAQ: BAYAU)
DMIIR vs BAYAU Comparison November 2026
Drugs Made In America Acquisition II Corp. (NASDAQ: DMIIR) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMIIR stands at 3.2M. In comparison, BAYAU has a market cap of 63.1M. Regarding current trading prices, DMIIR is priced at $0.05 on the NASDAQ, while BAYAU trades at $12.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMIIR currently has a P/E ratio of 0.25, whereas BAYAU's P/E ratio is 258.06. In terms of profitability, DMIIR's ROE is +0.03%, compared to BAYAU's ROE of -0.03%. Regarding short-term risk, DMIIR is less volatile compared to BAYAU. This indicates lower risk in terms of short-term price fluctuations for DMIIR.Check BAYAU's competition here
Blueport Acquisition Ltd (NASDAQ: BPACU)
DMIIR vs BPACU Comparison November 2026
Drugs Made In America Acquisition II Corp. (NASDAQ: DMIIR) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMIIR stands at 3.2M. In comparison, BPACU has a market cap of 61.3M. Regarding current trading prices, DMIIR is priced at $0.05 on the NASDAQ, while BPACU trades at $10.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMIIR currently has a P/E ratio of 0.25, whereas BPACU's P/E ratio is N/A. In terms of profitability, DMIIR's ROE is +0.03%, compared to BPACU's ROE of +0.01%. Regarding short-term risk, DMIIR is more volatile compared to BPACU. This indicates higher risk in terms of short-term price fluctuations for DMIIR.Check BPACU's competition here
Blueport Acquisition Ltd (NASDAQ: BPAC)
DMIIR vs BPAC Comparison November 2026
Drugs Made In America Acquisition II Corp. (NASDAQ: DMIIR) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMIIR stands at 3.2M. In comparison, BPAC has a market cap of 61.2M. Regarding current trading prices, DMIIR is priced at $0.05 on the NASDAQ, while BPAC trades at $10.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMIIR currently has a P/E ratio of 0.25, whereas BPAC's P/E ratio is N/A. In terms of profitability, DMIIR's ROE is +0.03%, compared to BPAC's ROE of +0.01%. Regarding short-term risk, DMIIR is less volatile compared to BPAC. This indicates lower risk in terms of short-term price fluctuations for DMIIR.Check BPAC's competition here
Cartesian Growth Corporation III (NASDAQ: CGCTW)
DMIIR vs CGCTW Comparison November 2026
Drugs Made In America Acquisition II Corp. (NASDAQ: DMIIR) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMIIR stands at 3.2M. In comparison, CGCTW has a market cap of 50.4M. Regarding current trading prices, DMIIR is priced at $0.05 on the NASDAQ, while CGCTW trades at $1.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMIIR currently has a P/E ratio of 0.25, whereas CGCTW's P/E ratio is N/A. In terms of profitability, DMIIR's ROE is +0.03%, compared to CGCTW's ROE of -0.15%. Regarding short-term risk, DMIIR is less volatile compared to CGCTW. This indicates lower risk in terms of short-term price fluctuations for DMIIR.Check CGCTW's competition here
YHN Acquisition I Limited (NASDAQ: YHNA)
DMIIR vs YHNA Comparison November 2026
Drugs Made In America Acquisition II Corp. (NASDAQ: DMIIR) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMIIR stands at 3.2M. In comparison, YHNA has a market cap of 47.7M. Regarding current trading prices, DMIIR is priced at $0.05 on the NASDAQ, while YHNA trades at $11.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMIIR currently has a P/E ratio of 0.25, whereas YHNA's P/E ratio is 85.54. In terms of profitability, DMIIR's ROE is +0.03%, compared to YHNA's ROE of +0.10%. Regarding short-term risk, DMIIR is less volatile compared to YHNA. This indicates lower risk in terms of short-term price fluctuations for DMIIR.Check YHNA's competition here
YHN Acquisition I Limited Unit (NASDAQ: YHNAU)
DMIIR vs YHNAU Comparison November 2026
Drugs Made In America Acquisition II Corp. (NASDAQ: DMIIR) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMIIR stands at 3.2M. In comparison, YHNAU has a market cap of 47.7M. Regarding current trading prices, DMIIR is priced at $0.05 on the NASDAQ, while YHNAU trades at $11.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMIIR currently has a P/E ratio of 0.25, whereas YHNAU's P/E ratio is 551.74. In terms of profitability, DMIIR's ROE is +0.03%, compared to YHNAU's ROE of +0.10%. Regarding short-term risk, DMIIR is less volatile compared to YHNAU. This indicates lower risk in terms of short-term price fluctuations for DMIIR.Check YHNAU's competition here
Sol Strategies Inc. (NASDAQ: STKE)
DMIIR vs STKE Comparison November 2026
Drugs Made In America Acquisition II Corp. (NASDAQ: DMIIR) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMIIR stands at 3.2M. In comparison, STKE has a market cap of 46.6M. Regarding current trading prices, DMIIR is priced at $0.05 on the NASDAQ, while STKE trades at $1.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMIIR currently has a P/E ratio of 0.25, whereas STKE's P/E ratio is -0.36. In terms of profitability, DMIIR's ROE is +0.03%, compared to STKE's ROE of -2.15%. Regarding short-term risk, DMIIR is less volatile compared to STKE. This indicates lower risk in terms of short-term price fluctuations for DMIIR.Check STKE's competition here